newsfilter
← Latest News
GlobeNewswire·

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

IMNN
  • IMUNON reported a net loss of $3.8 million ($0.64 per share) for Q3 2026, compared to $3.4 million ($1.16 per share) in Q3 2025.
  • Net loss for the nine months ended September 30, 2026, was $10.9 million ($2.01 per share), compared to $10.3 million ($5.53 per share) in the same period of 2025.
  • Phase 3 OVATION 3 enrollment for lead candidate IMNN-001 in advanced ovarian cancer is expected to complete by Q1 2029, supported by Phase 2 data showing significant overall survival benefit.
  • IMNN-001 is the first gene-based immunotherapy selected by the NCI/CTEP for partnered clinical development under a CRADA agreement.
  • The Company exchanged $1.2 million of debt for Series B Preferred Stock, reducing the A-1 Note balance by approximately 43% without issuing common stock.
  • IMUNON agreed to sell rights to ThermoDox to VoxelDox Therapeutics in exchange for equity, up to $16.5 million in milestone payments, and future royalties.
  • Research and development expenses were $1.8 million for Q3 2026 and $5.6 million for the nine months ended September 30, 2026.
  • Cash and cash equivalents totaled $4.0 million at September 30, 2026, with an additional $5.0 million in restricted cash.
  • New translational data from the Phase 2 OVATION 2 study were presented at the SITC 41st Annual Meeting held November 4–8, 2026.
  • A conference call to discuss Q3 2026 financial results \& business updates was scheduled for November 12, 2026, at 11:00 a.m. EST.
Company
Imunon, Inc.
Keywords
Nasdaq:IMNN, Imunon, Inc., IMUNON, Inc, Nasdaq: IMNN, clinical-stage, 2026 Financial Results, Business Update, DNA-mediated immunotherapy, IMNN-001